Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients

Inclusion Criteria:

• Adult patients of both genders

• Myocardial Infarction diagnosis

• Dyslipidemia diagnosis

• The first injection of inclisiran no later than 14 ± 5 days after theSTEMI/non-STEMI

• LDL-C > 5 mmol/L (statin-naive patients) or LDL-C > 2.5 mmol/L (on the basis ofstatin MTD) at the time of hospitalization or no target LDL-C level (> 1.4 mmol/L orno LDL-C level decrease by 50% on statin MTD + ezetimibe)

• Signed Informed Consent Form (ICF)

Exclusion Criteria:

• Severe oncological and somatic diseases with system and organ failure*

• Competing diseases that caused emergency hospitalization (pulmonary thromboembolism,aortic dissection)

• History of therapy with PCSK9 inhibitors

• Active inflammatory liver disease or the levels of AST, ALT > 3 times, or totalbilirubin > 2 times higher than the upper limit of norm

• Any other MACE in the anamnesis